The FDA Has Accepts Aquestive Therapeutics' New Drug Application For Anaphylm For Type 1 Allergic Reactions, Including Anaphylaxis, With PDUFA Target Action Date Of January 31, 2026

Benzinga · 06/16 11:04

If approved by the FDA, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.